Peptide Encyclopedia / Retatrutide + Cagrilintide
EncyclopediaRetatrutide plus cagrilintide is an experimental pairing of a GIP/GLP-1/glucagon triple agonist with an amylin analog, stacking appetite and energy-expenditure effects with amylin-driven satiety. Each drug is investigational on its own, and the combination has no dedicated trial data or approval. Educational only, not medical advice.
| Category | GLP-1 / Metabolic |
| Regulatory status | Not FDA-approved. |
An experimental pairing of retatrutide (a GIP/GLP-1/glucagon triple receptor agonist) with cagrilintide (amylin analog), combining incretin/glucagon appetite and energy-expenditure effects with amylin-mediated satiety. Each component is itself investigational.
uncertain; both components are designed for long-acting once-weekly dosing. Commonly reported use/dosing: No approved or validated protocol. Neither component is FDA-approved individually, and this specific blend is not an established or studied fixed-dose product in standard care; any circulation is via unregulated channels.
Not FDA-approved. Retatrutide and cagrilintide are separate investigational agents; this combination is not an approved or clinically standard product. Compounded/research-chemical use is gray-market and not sanctioned.
Expected pronounced GI effects (nausea, vomiting, diarrhea), possible heart-rate increase; combining multiple investigational agonists raises additive and poorly characterized risks. Long-term safety unknown; combining unapproved agents is not advised.
Components are in clinical development individually; this specific combination lacks robust dedicated clinical evidence and is not approved.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Retatrutide + Cagrilintide may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
